Dr Steve Felstead Joins Mironid as Chief Medical Officer (CMO)
March 5, 2018
March 5, 2018 – Mironid is delighted to announce the appointment of Dr Steve Felstead as Chief Medical Officer (CMO) Dr Felstead retired from the
March 5, 2018 – Mironid is delighted to announce the appointment of Dr Steve Felstead as Chief Medical Officer (CMO) Dr Felstead retired from the
Data supports biologic activity of APL-2 in reducing the growth rate of geographic atrophy CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 – Apellis Pharmaceuticals,
Third sector funder Inspiring Scotland has appointed Sinclair Dunlop of Epidarex Capital as chair of its board of trustees. He succeeds Niall Lothian, who has
Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million.
January 15, 2018 – Mironid is delighted to announce the appointment of Dr Enno Klussmann to our Scientific Advisory Board Dr. Klussmann is currently a
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to
RICHMOND, Va., December 19, 2017- Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected two
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 – Apellis Pharmaceuticals,Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the
Acquisition Marks Further Success for the Epidarex Portfolio Bethesda, Md., December 7, 2017 – Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, today
An interview with Sinclair Dunlop, Managing Partner at Epidarex Capital Sinclair Dunlop, Managing Partner at transatlantic venture capital firm Epidarex Capital, talks to Biotechand Money